Central carbon metabolism in the progression of mammary carcinoma

There is a growing belief that the metabolic program of breast tumor cells could be a therapeutic target. Yet, without detailed information on central carbon metabolism in breast tumors it is impossible to know which metabolic pathways to target, and how their inhibition might influence different stages of breast tumor progression. Here we perform the first comprehensive profiling of central metabolism in the MCF10 model of mammary carcinoma, where the steps of breast tumor progression (transformation, tumorigenicity and metastasis) can all be examined in the context of the same genetic background. The metabolism of [U-13C]-glucose by a series of progressively more aggressive MCF10 cell lines was tracked by 2D NMR and mass spectrometry. From this analysis the flux of carbon through distinct metabolic reactions was quantified by isotopomer modeling. The results indicate widespread changes to central metabolism upon cellular transformation including increased carbon flux through the pentose phosphate pathway (PPP), the TCA cycle, as well as increased synthesis of glutamate, glutathione and fatty acids (including elongation and desaturation). The de novo synthesis of glycine increased upon transformation as well as at each subsequent step of breast tumor cell progression. Interestingly, the major metabolic shift in metastatic cells is a large increase in the de novo synthesis of proline. This work provides the first comprehensive view of changes to central metabolism as a result of breast tumor progression.

[1]  F. Miller,et al.  Profiling the progression of cancer: Separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis , 2003, Proteomics.

[2]  J. Schouten,et al.  High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model , 2006, Breast Cancer Research and Treatment.

[3]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[4]  T. Ferenci,et al.  Global metabolite analysis: the influence of extraction methodology on metabolome profiles of Escherichia coli. , 2003, Analytical biochemistry.

[5]  F. Kuhajda,et al.  Fatty acid synthase and cancer: new application of an old pathway. , 2006, Cancer research.

[6]  F. Miller Xenograft Models of Premalignant Breast Disease , 2000, Journal of Mammary Gland Biology and Neoplasia.

[7]  Marta Cascante,et al.  K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. , 2005, Cancer research.

[8]  Marta Cascante,et al.  K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts , 2005 .

[9]  Chen Yang,et al.  Comparative Metabolomics of Breast Cancer , 2006, Pacific Symposium on Biocomputing.

[10]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[11]  D. Schoeller,et al.  Measurement of fractional lipid synthesis using deuterated water (2H2O) and mass isotopomer analysis. , 1994, The American journal of physiology.

[12]  E. Gabrielson,et al.  Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. , 2003, Experimental cell research.

[13]  S. Marshall Role of Insulin, Adipocyte Hormones, and Nutrient-Sensing Pathways in Regulating Fuel Metabolism and Energy Homeostasis: A Nutritional Perspective of Diabetes, Obesity, and Cancer , 2006, Science's STKE.

[14]  L. Gille,et al.  The Exogenous NADH Dehydrogenase of Heart Mitochondria Is the Key Enzyme Responsible for Selective Cardiotoxicity of Anthracyclines , 1998, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[15]  M. Guppy,et al.  Cancer metabolism: facts, fantasy, and fiction. , 2004, Biochemical and biophysical research communications.

[16]  K. Conklin Cancer chemotherapy and antioxidants. , 2004, The Journal of nutrition.

[17]  F. Berrino,et al.  Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. , 2001, Journal of the National Cancer Institute.

[18]  F. Miller,et al.  MCF10AT: a model for the evolution of cancer from proliferative breast disease. , 1996, The American journal of pathology.

[19]  J. Warrington,et al.  Identification of a Mammalian Long Chain Fatty Acyl Elongase Regulated by Sterol Regulatory Element-binding Proteins* , 2001, The Journal of Biological Chemistry.

[20]  T. Kurosu,et al.  BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells , 2003, Oncogene.

[21]  Fred R. Miller,et al.  Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.

[22]  F. Kuhajda Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. , 2000, Nutrition.

[23]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[24]  Huasheng Lu,et al.  Hypoxia-inducible Factor 1 Activation by Aerobic Glycolysis Implicates the Warburg Effect in Carcinogenesis* , 2002, The Journal of Biological Chemistry.

[25]  J. Yodoi,et al.  Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.

[26]  Michael E Phelps,et al.  Positron emission tomography scanning: current and future applications. , 2002, Annual review of medicine.

[27]  P. Hammerman,et al.  Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  W. Aclimandos,et al.  Erythrocyte stearic to oleic acid ratio in patients with ocular melanoma , 1992, Eye.

[29]  E. Heinzle,et al.  Mass spectrometry for metabolic flux analysis. , 1999, Biotechnology and bioengineering.

[30]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[31]  J. Swinnen,et al.  Increased lipogenesis in cancer cells: new players, novel targets , 2006, Current opinion in clinical nutrition and metabolic care.

[32]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[33]  M. Lippman,et al.  Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. , 1990, The Journal of biological chemistry.

[34]  R. A. Igal,et al.  Stearoyl-CoA Desaturase Is Involved in the Control of Proliferation, Anchorage-independent Growth, and Survival in Human Transformed Cells* , 2005, Journal of Biological Chemistry.

[35]  Marta Cascante,et al.  Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. , 1998, American journal of physiology. Endocrinology and metabolism.

[36]  J. Klaunig,et al.  The role of oxidative stress in carcinogenesis. , 2004, Annual review of pharmacology and toxicology.

[37]  A. Klein-Szanto,et al.  Transformation of Human Breast Epithelial Cells by c‐Ha‐ras Oncogene , 1991, Molecular carcinogenesis.

[38]  Adam L. Meadows,et al.  Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. , 2006, Metabolic engineering.

[39]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.